Current Open Trials at Grand Valley Oncology

By cancer site/type.

Expanded Access — COVID 19 This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Immunotherapy Side Effects
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Breast Cancer
Collection of Research Data and Samples >From Patients Who Experience Immunotherapy Side Effects

Nausea & Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Hematological Malignancies (Blood Related Cancers)
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy ((ANSWer))

Breast Cancer:
Polaris: Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study. As of 9/30/19, this study is closed and no longer accepting new patients.

Breast Cancer Weight Loss Study (BWEL Study)

GU Cancers (Bladder, Urothelial, Kidney, etc.):
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Metastatic Cancers:
Electronic Patient Reporting of Symptoms During Cancer Treatment (PRO-TECT)
*As of 3/6/19 Grand Valley Oncology has reached maximum number of participants for this study. Website will be updated if our site is allowed to enroll additional participants.

Melanoma:
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Leukemia (CLL):
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia

Lung
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

Expanded Access / Compassionate Use:
Please contact the Grand Valley Oncology Clinical Trial Team at 970-644-4460 or gvoclinicals@gjhosp.org to discuss Expanded Access / Compassionate Use programs that may be available.

Click here to learn more about Hunstman Cancer Institute clinical trials.

Click here to search for clinical trials at other locations.